Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The Innovative Medicines Initiative: an engine for regulatory science


Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and the lessons learned.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


The opinions expressed in this article do not necessarily represent the opinions and positions of the European Commission, EFPIA, EMA or IMI.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Michel Goldman.

Ethics declarations

Competing interests

Michel Goldman and Nathalie Seigneuret are appointed by the Innovative Medicines Initiative (IMI). Hans-Georg Eichler is a member of the IMI Scientific Committee and is appointed by the European Medicines Agency, which is a partner of some IMI consortia.

Related links

Related links










Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldman, M., Seigneuret, N. & Eichler, HG. The Innovative Medicines Initiative: an engine for regulatory science. Nat Rev Drug Discov 14, 1–2 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research